Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

Immunological Reviews

Volumn 199, Issue , 2004, Pages 9-26

  Heath, William R ^a   Belz, Gabrielle T ^a   Behrens, Georg M N ^a   Smith, Christopher M ^a   Forehan, Simon P ^a   Parish, Ian A ^a   Davey, Gayle M ^a   Wilson, Nicholas S ^a   Carbone, Francis R ^b   Villadangos, Jose A ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIGEN; DNA VACCINE;

CELL DIFFERENTIATION; CELL FUNCTION; CELL SUBPOPULATION; CROSS TOLERANCE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY; VACCINATION; VIRUS INFECTION;

ANIMALS; ANTIGENS; ANTIGENS, SURFACE; CROSS-PRIMING; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; VACCINES, DNA;

EID: 2942541735     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00142.x     Document Type: Review

References (142)

1. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003;425:397-402.
2. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 2003;100:12889-12894.
3. Houde M, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003;425:402-406.
4. Cresswell P, Bangia N, Dick T, Diedrich G. The nature of the MHC class I peptide loading complex. Immunol Rev 1999;172:21-28.
5. Jarosch E, Geiss-Friedlander R, Meusser B, Walter J, Sommer T. Protein dislocation from the endoplasmic reticulum - pulling out the suspect. Traffic 2002;3:530-536.
6. Romisch K. Surfing the Sec61 channel: bidirectional protein translocation across the ER membrane. J Cell Sci 1999;112:4185-4191.
7. Matlack KE, Mothes W, Rapoport TA. Protein translocation: tunnel vision. Cell 1998;92:381-390.
8. Wiertz EJ, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996;384:432-438.
9. Lizee G, et al. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol 2003;4:1065-1073.
10. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
11. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells In vivo. J Exp Med 2000;192:1685-1696.
12. + dendritic cells. J Immunol 2001;166:5327-5330.
13. den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 2002;196:817-827.
14. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002;195:1289-1302.
15. Ke Y, Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J Exp Med 1996;184:1179-1184.
16. + T cells results in antigen-specific T-cell tolerance. Nat Med 2000;6:1348-1354.
17. + T cells. J Exp Med 2003;197:643-656.
18. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993;90:4942-4946.
19. Rock KL, Rothstein L, Gamble S, Fleischacker C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol 1993;150:438-446.
20. Kovacsovics-Bankowski M, Rock KL. Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines. Eur J Immunol 1994;24:2421-2428.
21. Debrick JE, Campbell PA, Staerz US. Macrophages as accessory cells for class I MHC-restricted immune responses. J Immunol 1991;147:2846-2851.
22. Ramirez MC, Sigal LJ. Macrophages and dendritic cells use the cytosolic pathway to rapidly cross-present antigen from live, vaccinia-infected cells. J Immunol 2002;169:6733-6742.
23. Staerz UD, Karasuyama H, Garner AM. Cytotoxic T lymphocytes against a soluble protein. Nature 1987;329:449-451.
24. Regnault A, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-380.
25. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993;361:359-362.
26. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002;168:3992-4000.
27. Gooding LR, Edwards CB. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes. J Immunol 1980;124:1258-1262.
28. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
29. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
30. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996;4:349-355.
31. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990;171:377-387.
32. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-1288.
33. Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996;184:923-930.
34. Morgan DJ, Kurts C, Kreuwel HT, Holst KL, Heath WR, Sherman LA. Ontogeny of T cell tolerance to peripherally expressed antigens. Proc Natl Acad Sci USA 1999;96:3854-3858.
35. Mintern JD, Belz G, Gerondakis S, Carbone FR, Heath WR. The cross-priming APC requires a Rel-dependent signal to induce CTL. J Immunol 2002;168:3283-3287.
36. Bevan MJ. Antigen recognition. Class discrimination in the world of immunology. Nature 1987;325:192-194.
37. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, Fruh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci USA 1996;93:10990-10995.
38. Fruh K, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-418.
39. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997;94:12616-12621.
40. Ploegh HL. Viral strategies of immune evasion. Science 1998;280:248-253.
41. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol 2000;18:861-926.
42. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001;166:3717-3723.
43. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol 2003;170:2302-2309.
44. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2:185-194.
45. Zitvogel L, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998;4:594-600.
46. Wolfers J, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7:297-303.
47. Albert ML, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-1368.
48. Larsson M, et al. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 2001;31:3432-3442.
49. Arrode G, et al. Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8 (+) T cells by dendritic cells. J Virol 2000;74:10018-10024.
50. Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 2002;168:5589-5595.
51. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WK. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998;188:409-414.
52. Sasaki S, Xin KQ, Okudela K, Okuda K, Ishii N. Immunomodulation by apoptosis-inducing caspases for an influenza DNA vaccine delivered by gene gun. Gene Ther 2002;9:828-831.
53. Sasaki S, Amara RR, Oran AE, Smith JM, Robinson HL. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 2001;19:543-547.
54. Singh-Jasuja H, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000;191:1965-1974.
55. Arnold-Schild D, et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 1999;162:3757-3760.
56. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic 2002;3:321-330.
57. Li M, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099-6103.
58. Schulz O, Reis E, Sousa C. Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology 2002;107:183-189.
59. + T cells engaging class II molecules in cholesterol-rich domains. J Immunol 2002;168:1172-1180.
60. Datta SK, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003;170:4102-4110.
61. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 2003;198:111-122.
62. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997;186:239-245.
63. + T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA 1999;96:12703-12707.
64. Belz GT, et al. The CD8alpha (+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099-1104.
65. Davey GM, et al. Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J Exp Med 2002;196:947-955.
66. Kundig TM, et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995;268:1343-1347.
67. Ochsenbein A, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-1069.
68. Ohashi PS, et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-317.
69. Bevan MJ. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 1976;117:2233-2238.
70. Jung S, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002;17:211-220.
71. Smith CM, et al. Cutting edge: conventional CD8alpha(+) dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 2003;170:4437-4440.
72. + T cells by infected dendritic cells in vivo. Nat Immunol 2002;3:265-271.
73. Heath WR, Carbone ER. Cross-presentation in viral immunity and self-tolerance. Nature Rev Immunol 2001;1:126-134.
74. Prasad SA, Norbury CC, Chen W, Bennink JR, Yewdell JW. Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Immunol 2001;166:4809-4812.
75. Gold MC, Munks MW, Wagner M, Koszinowski US, Hill AB, Fling SP. The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J Immunol 2002;169:359-365.
76. Basta S, Chen W, Bennink JR, Yewdell JW. Inhibitory effects of cytomegalovirus proteins US2 and US11 point to contributions from direct priming and cross-priming in induction of vaccinia virus-specific CD8(+) T cells. J Immunol 2002;168:5403-5408.
77. Allan RS, et al. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans' cells. Science 2003;301:1925-1928.
78. + dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004;172:1996-2000.
79. Sigal LJ, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J Exp Med 2000;192:1143-1150.
80. Lenz LL, Butz EA, Bevan MJ. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J Exp Med 2000;192:1135-1142.
81. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 2003;4:733-739.
82. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-161.
83. Wilson NS, Villadangos JA. Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm. Immunol Cell Biol 2004;82:91-98.
84. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 2000;164:2978-2986.
85. Henri S, et al. The dendritic cell populations of mouse lymph nodes. J Immunol 2001;167:741-748.
86. O'Keeffe M, et al. Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med 2002;196:1307-1319.
87. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002;100:1734-1741.
88. Kamath AT, et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 2000;165:6762-6770.
89. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997;185:1101-1111.
90. Asselin-Paturel C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001;2:1144-1150.
91. Nakano H, Yanagita M, Gunn MD. CD11c(+) B220(+) Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001;194:1171-1178.
92. Cella M, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-923.
93. Diebold SS, et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003;424:324-328.
94. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-1015.
95. Vremec D, et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med 1992;176:47-58.
96. Valladeau J, et al. Langerin, a novel C-type lectin specific to Langerhans' cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71-81.
97. Kadowaki N, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-869.
98. Romani N, Holzmann S, Tripp CH, Koch F, Stoitzner P. Langerhans' cells - dendritic cells of the epidermis. APMIS 2003;111:725-740.
99. Macatonia SE, Knight SC, Edwards AJ, Griffiths S, Fryer P. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med 1987;166:1654-1667.
100. Garg S, et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 2003;4:907-912.
101. Zhao X, et al. Vaginal submucosal dendritic cells, but not Langerhans' cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 2003;197:153-162.
102. + T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells. J Exp Med 2003;198:201-209.
103. Von Stebut E, et al. Interleukin 1 alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 2003;198:191-199.
104. Itano AA, et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003;19:47-57.
105. Hochrein H, Shortman K, Vremec D, Scott B, Hertzog P, O'Keeffe M. Differential production of IL-12, IFN-alpha, and IFN-garnma by mouse dendritic cell subsets. J Immunol 2001;166:5448-5455.
106. Pulendran B, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999;96:1036-1041.
107. Steinman RM, Pack M, Inaba K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev 1997;156:25-37.
108. Pulendran B, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol 1997;159:2222-2231.
109. De Smedt T, et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996;184:1413-1424.
110. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003;197:1141-1151.
111. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002;196:1079-1090.
112. Valdez Y, Mah W, Winslow MM, Xu L, Ling P, Townsend SE. Major histocompatibility complex class II presentation of cell-associated antigen is mediated by CD8alpha (+) dendritic cells in vivo. J Exp Med 2002;195:683-694.
113. Behrens GMN, et al. Helper requirements for generation of effector CTL to islet β cell antigens. J Immunol 2004 (in press).
114. + T cell help. J Exp Med 1997;186:65-70.
115. Hugues S, et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity 2002;16:169-181.
116. Turley S, Poirot L, Hattori M, Benoist C, Mathis D. Physiological {beta} cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 2003;198:1527-1537.
117. Morelli AE, et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 2003;101: 611-620.
118. + T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 2002;195:1233-1245.
119. Heath WR, Carbone FR. Immunology: dangerous liaisons. Nature 2003;425:460-461.
120. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
121. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54:1-13.
122. Fuchs E. Two signal model of lymphocyte activation. Immunol Today 1992;13:462.
123. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-1255.
124. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-521.
125. Sato Y, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-354.
126. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158:3635-3639.
127. Hemmi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
128. Martin-Orozco E, Kobayashi H, Van Uden J, Nguyen MD, Kornbluth RS, Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol 1999;11:1111-1118.
129. Sparwasser T, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28:2045-2054.
130. Spies B, et al. Vaccination with plasmid DNA activates dendritic cells via toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003;171:5908-5912.
131. + T cells after gene gun immunization. J Exp Med 1998;188:1075-1082.
132. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164:558-561.
133. Doe B, Selby M, Barnett S, Baenziger J, Walker CM. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA 1996;93:8578-8583.
134. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996;184:1555-1560.
135. Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997;159:11-14.
136. Merad M, et al. Langerhans' cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002;3:1135-1141.
137. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999;189:169-178.
138. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996;2:1122-1128.
139. Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997;186:1481-1486.
140. Corr M, von Damm A, Lee DJ, Tighe H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 1999;163:4721-4727.
141. Cho JH, Youn JW, Sung YC. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001;167:5549-5557.
142. Kim TW, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109-117.